Besonderheiten in der Nachsorge von gastrointestinalen Tumoren

Abstract

Treatment for gastrointestinal malignancies has evolved over the past two decades. Long-term outcomes have considerably improved, however a high rate of recurrence persists. With the exception of colon cancer, clear consensus strategies with regards to post-treatment surveillance are lacking. Current surveillance practices in non-colon cancer cases are inadequately based on retrospective case analyses and expert recommendations which are not uniformly consistent.

This article presents the key follow-up aspects such as recurrence frequency, timing, localization, and therapeutic efficacy for the most common gastrointestinal tumors, and summarizes current recommendations for early detection of recurrence. In particular, we compare and contrast the recommendations of the German S3 guideline, the European Society for Medical Oncology (ESMO) and the American National Comprehensive Cancer Network (NCCN).

Nach abgeschlossener Tumortherapie stellt die Nachsorge eine wichtige Säule in der Betreuung gastroonkologischer Patienten dar. Nicht nur das Erkennen und Behandeln von Folgestörungen gehört dazu, sondern auch die frühzeitige Diagnose von Rezidiven. Ein klarer Nachsorgeplan sowie eine gute Zusammenarbeit zwischen Hausärzten und den Fachdisziplinen spielen hier eine entscheidende Rolle.

Schlüsselwörter

Nachsorge - Tumornachsorge - Follow-up - Rezidiv - Rezidivfrüherkennung - Früherkennung - Screening - Karzinom - Krebs - Tumor - Empfehlung - S3-Leitlinie - ESMO - NCCM - Fachgesellschaften - gastrointestinale Tumore - Ösophaguskarzinom - Magenkarzinom - HCC - Hepatozelluläres - Pankreaskarzinom - Kolonkarzinom - Rektumkarzinom - Kolorektales Karzinom

Key words

cancer - carcinoma - tumor - malignancy - gastrointestinal - oncology - guideline - surveillance - follow-up - aftercare - survivorship - screening - recurrence - German Guideline Programm in Oncology - German S3 guideline - European Society for Medical Oncology - ESMO - American National Comprehensive Cancer Network - NCCN - esophageal - gastric - oesophagealgastric - AEG - panceratic - pancreas - hepatocellular - HCC - colon - colorectal

• Literatur

• 1 Moorcraft SY, Fontana E, Cunningham D. et al. Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. BMC Cancer 2016; 16: 112 . doi:10.1186/s12885-016-2145-0
• 2 Katz MH, Wang H, Fleming JB. et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16: 836-847 . doi:10.1245/s10434-008-0295-2
• 3 van der Stok EP, Spaander MCW, Grunhagen DJ. et al. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol 2017; 14: 297-315 . doi:10.1038/nrclinonc.2016.199
• 4 Antonowicz SS, Lorenzi B, Parker M. et al. Annual computed tomography scans do not improve outcomes following esophagectomy for cancer: a 10-year UK experience. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus 2015; 28: 365-370 . doi:10.1111/dote.12209
• 5 Abate E, DeMeester SR, Zehetner J. et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg 2010; 210: 428-435 . doi:10.1016/j.jamcollsurg.2010.01.006
• 6 Lou F, Sima CS, Adusumilli PS. et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer 2013; 8: 1558-1562 . doi:10.1097/01.JTO.0000437420.38972.fb
• 7 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinien. Im Internet: http://www.leitlinienprogramm-onkologie.de Stand: 9.9.2017
• 8 Lordick F, Mariette C, Haustermans K. et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v50-v57 . doi:10.1093/annonc/mdw329
• 9 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Im Internet: https://www.nccn.org Stand: 9.9.2017
• 10 Aurello P, Petrucciani N, Antolino L. et al. Follow-up after curative resection for gastric cancer: Is it time to tailor it?. World J Gastroenterol 2017; 23: 3379-3387 . doi:10.3748/wjg.v23.i19.3379
• 11 Sisic L, Strowitzki MJ, Blank S. et al. Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis. Gastric cancer 2017;
• 12 Smyth EC, Verheij M, Allum W. et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27: v38-v49 . doi:10.1093/annonc/mdw350
• 13 Ikoma N, Chen HC, Wang X. et al. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol 2017; 24: 2679-2687 . doi:10.1245/s10434-017-5838-y
• 14 Chong CS, Ng CW, Shabbir A. et al. Computed tomography of the thorax for gastric cancer staging: Is it necessary?. Scand J Surg 2015; 104: 244-247 . doi:10.1177/1457496915571400
• 15 Peeters M, Lerut T, Vlayen J. et al. Guideline for the esophageal and gastric cancer: scientific support of the College of Oncology. In: KCE Reports. Brussels: Belgian Health Care Knowledge Centre (KCE); 2008
• 16 Baiocchi GL, D’Ugo D, Coit D. et al. Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Gastric Cancer 2016; 19: 15-20 . doi:10.1007/s10120-015-0513-0
• 17 Le AT, Tzeng CW. Does finding early recurrence improve outcomes, and at what cost?. J Surg Oncol 2016; 114: 329-335 . doi:10.1002/jso.24370
• 18 Tzeng CW, Abbott DE, Cantor SB. et al. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol 2013; 20: 2197-2203 . doi:10.1245/s10434-013-2889-6
• 19 Tzeng CW, Fleming JB, Lee JE. et al. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB: the official journal of the International Hepato Pancreato Biliary Association 2012; 14: 365-372 . doi:10.1111/j.1477-2574.2012.00445.x
• 20 Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. Onkopedia Leitlinie: Pankreaskarzinom (Juli 2017). Im Internet: https://www.onkopedia.com/de Stand: 9.9.2017
• 21 Ducreux M, Cuhna AS, Caramella C. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26 (Suppl. 05) v56-v68 . doi:10.1093/annonc/mdv295
• 22 Robert Koch-Insitut. Zentrum für Krebsregisterdaten. Im Internet: http://www.krebsdaten.de Stand: 9.9.2017
• 23 Meniconi RL, Komatsu S, Perdigao F. et al. Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection. Surgery 2015; 157: 454-462 . doi:10.1016/j.surg.2014.10.011
• 24 El-Serag HB. Hepatocellular carcinoma. New Engl J Med 2011; 365: 1118-1127 . doi:10.1056/NEJMra1001683
• 25 Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: vii41-vii48 . doi:10.1093/annonc/mds225
• 26 Makhoul R, Alva S, Wilkins KB. Surveillance and Survivorship after Treatment for Colon Cancer. Clin Colon Rectal Surg 2015; 28: 262-270 . doi:10.1055/s-0035-1564435
• 27 Primrose JN, Perera R, Gray A. et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. Jama 2014; 311: 263-270 . doi:10.1001/jama.2013.285718
• 28 Glynne-Jones R, Wyrwicz L, Tiret E. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv22-iv40 . doi:10.1093/annonc/mdx224
• 29 Labianca R, Nordlinger B, Beretta G. et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: vi64-vi72